Early Access — free while we kick the tires
EdgarHawk

Givens John F. II

Chief Executive Officer

Director Officer
2 filings analyzed · 1 company · Latest 2025-11-19

Never miss a filing from Givens John F. II

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
VirTra, Inc VTSI 2 0 Net buying

Activity

November 2025
2025-11-19 VirTra, Inc VTSI
low
Buy
22 shares
$108
Significance 3/10

CEO Givens buys 22 shares of VTSI for $108.31 (blended $4.92); stock down 38.4% from 52-week high.

John F. Givens II, Chief Executive Officer of VirTra, Inc., filed 4 separate purchases on 2025-11-19 totaling 22 shares for $108.31 at a blended average price of $4.92, increasing his post-transaction holdings from 328,366 to 328,388 shares (+0.0%). The transaction occurred as the stock trades at $4.90, down 38.4% from its 52-week high of $7.96 and declined 15.4% over the prior 30 days. VirTra's fundamentals show revenue contraction with annual growth at -30.7%, a net loss of $388.6K on $5.3M quarterly revenue, and a market cap of $55.4M. Givens purchased an additional 30 shares on 2025-11-18 (the day prior), indicating consecutive buying activity, though the company's negative earnings and declining revenue trajectory are material context for assessing the signal.

2025-11-18 VirTra, Inc VTSI
high
Buy
4,978 shares
$23,743
Significance 6/10

CEO Givens buys 4,978 shares ($23.7K) across 18 transactions at VirTra (VTSI) at blended $4.77, stock down 41.6% from 52-week high

John F. Givens II, Chief Executive Officer, executed 18 separate purchases totaling 4,978 shares for $23,742.92 between November 14–18, 2025, at prices ranging from $4.72 to $5.02 with a blended average of $4.77. The transaction increased his holdings from 323,388 to 328,366 shares (+1.5%). This buying activity occurs amid material headwinds: VirTra reports annual revenue decline of -30.7%, the most recent quarter shows net loss of $-388,567.00 on revenue of $5,349,993.00, and the stock trades at $4.77—down 41.6% from its 52-week high of $8.17 and down 15.6% over the past 30 days. The sustained accumulation across multiple transaction dates and price points, concurrent with declining fundamentals and deteriorating share price, warrants examination of whether this reflects management's assessment of intrinsic value or a broader deterioration in company prospects.

Related insiders